Cargando…

Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers

Accurate assessment of SARS‐CoV‐2 immunity is critical in evaluating vaccine efficacy and devising public health policies. Whilst the exact nature of effective immunity remains incompletely defined, SARS‐CoV‐2‐specific T‐cell responses are a critical feature that will likely form a key correlate of...

Descripción completa

Detalles Bibliográficos
Autores principales: Scurr, Martin J., Zelek, Wioleta M., Lippiatt, George, Somerville, Michelle, Burnell, Stephanie E. A., Capitani, Lorenzo, Davies, Kate, Lawton, Helen, Tozer, Thomas, Rees, Tara, Roberts, Kerry, Evans, Mererid, Jackson, Amanda, Young, Charlotte, Fairclough, Lucy, Tighe, Paddy, Wills, Mark, Westwell, Andrew D., Morgan, B. Paul, Gallimore, Awen, Godkin, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653009/
https://www.ncbi.nlm.nih.gov/pubmed/34775604
http://dx.doi.org/10.1111/imm.13433
_version_ 1784611629584875520
author Scurr, Martin J.
Zelek, Wioleta M.
Lippiatt, George
Somerville, Michelle
Burnell, Stephanie E. A.
Capitani, Lorenzo
Davies, Kate
Lawton, Helen
Tozer, Thomas
Rees, Tara
Roberts, Kerry
Evans, Mererid
Jackson, Amanda
Young, Charlotte
Fairclough, Lucy
Tighe, Paddy
Wills, Mark
Westwell, Andrew D.
Morgan, B. Paul
Gallimore, Awen
Godkin, Andrew
author_facet Scurr, Martin J.
Zelek, Wioleta M.
Lippiatt, George
Somerville, Michelle
Burnell, Stephanie E. A.
Capitani, Lorenzo
Davies, Kate
Lawton, Helen
Tozer, Thomas
Rees, Tara
Roberts, Kerry
Evans, Mererid
Jackson, Amanda
Young, Charlotte
Fairclough, Lucy
Tighe, Paddy
Wills, Mark
Westwell, Andrew D.
Morgan, B. Paul
Gallimore, Awen
Godkin, Andrew
author_sort Scurr, Martin J.
collection PubMed
description Accurate assessment of SARS‐CoV‐2 immunity is critical in evaluating vaccine efficacy and devising public health policies. Whilst the exact nature of effective immunity remains incompletely defined, SARS‐CoV‐2‐specific T‐cell responses are a critical feature that will likely form a key correlate of protection against COVID‐19. Here, we developed and optimized a high‐throughput whole blood‐based assay to determine the T‐cell response associated with prior SARS‐CoV‐2 infection and/or vaccination amongst 231 healthy donors and 68 cancer patients. Following overnight in vitro stimulation with SARS‐CoV‐2‐specific peptides, blood plasma samples were analysed for T(H)1‐type cytokines. Highly significant differential IFN‐γ(+)/IL‐2(+) SARS‐CoV‐2‐specific T‐cell responses were seen amongst previously infected COVID‐19‐positive healthy donors in comparison with unknown / naïve individuals (p < 0·0001). IFN‐γ production was more effective at identifying asymptomatic donors, demonstrating higher sensitivity (96·0% vs. 83·3%) but lower specificity (84·4% vs. 92·5%) than measurement of IL‐2. A single COVID‐19 vaccine dose induced IFN‐γ and/or IL‐2 SARS‐CoV‐2‐specific T‐cell responses in 116 of 128 (90·6%) healthy donors, reducing significantly to 27 of 56 (48·2%) when measured in cancer patients (p < 0·0001). A second dose was sufficient to boost T‐cell responses in the majority (90·6%) of cancer patients, albeit IFN‐γ(+) responses were still significantly lower overall than those induced in healthy donors (p = 0·034). Three‐month post‐vaccination T‐cell responses also declined at a faster rate in cancer patients. Overall, this cost‐effective standardizable test ensures accurate and comparable assessments of SARS‐CoV‐2‐specific T‐cell responses amenable to widespread population immunity testing, and identifies individuals at greater need of booster vaccinations.
format Online
Article
Text
id pubmed-8653009
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86530092021-12-08 Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers Scurr, Martin J. Zelek, Wioleta M. Lippiatt, George Somerville, Michelle Burnell, Stephanie E. A. Capitani, Lorenzo Davies, Kate Lawton, Helen Tozer, Thomas Rees, Tara Roberts, Kerry Evans, Mererid Jackson, Amanda Young, Charlotte Fairclough, Lucy Tighe, Paddy Wills, Mark Westwell, Andrew D. Morgan, B. Paul Gallimore, Awen Godkin, Andrew Immunology Original Articles Accurate assessment of SARS‐CoV‐2 immunity is critical in evaluating vaccine efficacy and devising public health policies. Whilst the exact nature of effective immunity remains incompletely defined, SARS‐CoV‐2‐specific T‐cell responses are a critical feature that will likely form a key correlate of protection against COVID‐19. Here, we developed and optimized a high‐throughput whole blood‐based assay to determine the T‐cell response associated with prior SARS‐CoV‐2 infection and/or vaccination amongst 231 healthy donors and 68 cancer patients. Following overnight in vitro stimulation with SARS‐CoV‐2‐specific peptides, blood plasma samples were analysed for T(H)1‐type cytokines. Highly significant differential IFN‐γ(+)/IL‐2(+) SARS‐CoV‐2‐specific T‐cell responses were seen amongst previously infected COVID‐19‐positive healthy donors in comparison with unknown / naïve individuals (p < 0·0001). IFN‐γ production was more effective at identifying asymptomatic donors, demonstrating higher sensitivity (96·0% vs. 83·3%) but lower specificity (84·4% vs. 92·5%) than measurement of IL‐2. A single COVID‐19 vaccine dose induced IFN‐γ and/or IL‐2 SARS‐CoV‐2‐specific T‐cell responses in 116 of 128 (90·6%) healthy donors, reducing significantly to 27 of 56 (48·2%) when measured in cancer patients (p < 0·0001). A second dose was sufficient to boost T‐cell responses in the majority (90·6%) of cancer patients, albeit IFN‐γ(+) responses were still significantly lower overall than those induced in healthy donors (p = 0·034). Three‐month post‐vaccination T‐cell responses also declined at a faster rate in cancer patients. Overall, this cost‐effective standardizable test ensures accurate and comparable assessments of SARS‐CoV‐2‐specific T‐cell responses amenable to widespread population immunity testing, and identifies individuals at greater need of booster vaccinations. John Wiley and Sons Inc. 2021-12-06 2022-02 /pmc/articles/PMC8653009/ /pubmed/34775604 http://dx.doi.org/10.1111/imm.13433 Text en © 2021 The Authors. Immunology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Scurr, Martin J.
Zelek, Wioleta M.
Lippiatt, George
Somerville, Michelle
Burnell, Stephanie E. A.
Capitani, Lorenzo
Davies, Kate
Lawton, Helen
Tozer, Thomas
Rees, Tara
Roberts, Kerry
Evans, Mererid
Jackson, Amanda
Young, Charlotte
Fairclough, Lucy
Tighe, Paddy
Wills, Mark
Westwell, Andrew D.
Morgan, B. Paul
Gallimore, Awen
Godkin, Andrew
Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers
title Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers
title_full Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers
title_fullStr Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers
title_full_unstemmed Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers
title_short Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers
title_sort whole blood‐based measurement of sars‐cov‐2‐specific t cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653009/
https://www.ncbi.nlm.nih.gov/pubmed/34775604
http://dx.doi.org/10.1111/imm.13433
work_keys_str_mv AT scurrmartinj wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT zelekwioletam wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT lippiattgeorge wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT somervillemichelle wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT burnellstephanieea wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT capitanilorenzo wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT davieskate wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT lawtonhelen wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT tozerthomas wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT reestara wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT robertskerry wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT evansmererid wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT jacksonamanda wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT youngcharlotte wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT faircloughlucy wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT tighepaddy wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT willsmark wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT westwellandrewd wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT morganbpaul wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT gallimoreawen wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers
AT godkinandrew wholebloodbasedmeasurementofsarscov2specifictcellsrevealsasymptomaticinfectionandvaccineimmunogenicityinhealthysubjectsandpatientswithsolidorgancancers